|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||87.23 - 87.98|
|52 Week Range||63.68 - 91.95|
|PE Ratio (TTM)||-4.25|
|Earnings Date||Nov 8, 2017 - Nov 13, 2017|
|Forward Dividend & Yield||0.64 (0.73%)|
|1y Target Est||83.00|
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding PRGO totaled $4.24 billion.
Here are the sectors that made the biggest moves today: Perrigo’s (PRGO) gain led pharmaceuticals higher. Recreational products gained, including Mattel (MAT). DaVita (DVA) boosted medical and nursing ...
TASE: PRGO) today announced it has initiated shipments to retail customers of the first-to-market over-the-counter ("OTC") store brand equivalent of Nexium® 24HR (esomeprazole magnesium) capsules. This product is packaged and marketed as store brands or retailer 'own label' brands and provides consumers a high-quality, value alternative to Nexium® 24HR capsules.
Everyone knows high prescription drug prices are a problem, but except for pharma stockholders, few people may realize that price cuts are rippling through the generic side of the industry.
TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing Exalgo® 32mg extended release tablets (hydromorphone HCl). The company anticipates launching this product by the end of September 2017. Exalgo® 32mg extended release tablets (hydromorphone HCl) is an opioid agonist indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.
Perrigo Co. said early Monday that the Food and Drug Administration has granted tentative approval for its generic version of the acne gel Acanya. Perrigo shares rose 1.2% in premarket trade after the ...
TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Acanya® (clindamycin phosphate and benzoyl peroxide) topical gel 1.2%/2.5%. Acanya® (clindamycin phosphate and benzoyl peroxide) topical gel 1.2%/2.5% is indicated for the topical treatment of acne vulgaris in patients 12 years or older. Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "The R&D team continues its efforts to achieve regulatory approvals for important new products.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Perrigo Co. Plc Here are 5 ETFs with the largest exposure to PRGO-US. Comparing the performance and risk of Perrigo Co. Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Perrigo's (PRGO) shares rise with Jeff Smith, CEO of Starboard Value, certifying the company as a top investment pick, courtesy its highly potential generic business.
Shares of Perrigo Co. surged Tuesday after Jeff Smith, chief executive officer of Starboard Value, singled out the pharmaceutical company as a good investment. Perrigo has more potential to boost sales ...
The distribution channel of Amazon.com Inc. represents a big opportunity for drug maker Perrigo, Starboard Value founder and CEO Jeffrey Smith said on Tuesday. Smith, speaking at the Delivering Alpha event ...
Starboard Value Jeffrey Smith pitched store-brand pharmaceutical company Perrigo as his best investment idea now, during a conference Tuesday.
There’s no doubt that Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has made some progress so far this year. Bankruptcy risk seemed material for Valeant stock as recently as earlier this year. Under CEO Joe Papa, however, VRX stock has at least has bought itself some time.
The White House is eliminating a crucial part of the Affordable Care Act. President Donald Trump wants to immediately stop payments to insurers. The administration said the government cannot legally continue to make payments. Yahoo Finance’s Alexis Christoforous and Rick Newman figure out how this will impact the insurance industry and patients.
President Trump's healthcare bill may have died in Congress, but that's not stopping him from making changes to Obamacare. Later today, the president is expected to sign an executive order that would let Americans buy insurance across state lines. Yahoo Finance’s Alexis Christoforous and Editor-in-Chief Andy Serwer figure out if the the president’s move will help lower premiums.
Activist investor and CEO of Starboard Value Jeff Smith speaks at Delivering Alpha 2017 about one stock he thinks will benefit from Amazon’s expansion into consumer products.
CNBC's Dominic Chu reports on the best stock picks as laid out by Starboard's Jeff Smith at the Delivering Alpha Conference.